Evidence map›Paper›PMID 32084506›Full record

ArticleAntiviral research2020

7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.

Sanae Hayashi, Nobuyo Higashi-Kuwata, Debananda Das, Kota Tomaya, Kohei Yamada, Shuko Murakami, David J Venzon, Shin-Ichiro Hattori, Masanori Isogawa, Stefan G Sarafianos and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sanae HayashiDepartment of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, Tokyo, Japan.
Debananda DasExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kota TomayaBiochemicals Division, Yamasa Corporation, Choshi, Chiba, Japan.
Kohei YamadaBiochemicals Division, Yamasa Corporation, Choshi, Chiba, Japan.
Shuko MurakamiDepartment of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
David J VenzonBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shin-Ichiro HattoriDepartment of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, Tokyo, Japan.
Masanori IsogawaDepartment of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Stefan G SarafianosLaboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health & Medicine Research Institute, Tokyo, Japan; Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Department of Clinical Sciences, Kumamoto University Hospital, Kumamoto, Japan. Electronic address: hiroaki.mitsuya2@nih.gov.
Yasuhito TanakaDepartment of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Electronic address: ytanaka@med.nagoya-cu.ac.jp.

Funding

Office of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5M
Development of Novel Agents Active against Hepatitis B VirusZIABC011486 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MITSUYA, HIROAKI · 2013 to 2025
$3.0M
Taking aim at HBV eradication using novel NRTIs and Capsid effectorsR01AI121315 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G, WANG, ZHENGQIANG · 2016 to 2020
$3.0M
Intramural NIH HHS ZIA BC011486NIAID NIH HHS R01 AI121315
6 · The paper itself

Abstract

We designed, synthesized and identified a novel nucleoside derivative, 4'-C-cyano-7-deaza-7-fluoro-2'-deoxyadenosine (CdFA), which exerts potent anti-HBV activity (IC

Indexed as

Drug Resistance, ViralAdenineAnimalsAntiviral AgentsGuanineHepatitis B, ChronicHepatitis B virusHep G2 CellsHumansMiceMice, TransgenicModels, MolecularNucleosidesOrganophosphonatesViral LoadadefovirAdenineAntiviral AgentsentecavirGuanineNucleosidesOrganophosphonatesAdefovirAnti-HBV drugsDrug resistanceEntecavirHBVNucleoside/nucleotide reverse transcriptase inhibitors

Identifiers

PMID32084506
PMCPMC7164687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.